Arthralgia

Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California

Retrieved on: 
Thursday, February 29, 2024

Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.

Key Points: 
  • Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • The dogs enrolled in this study had been diagnosed with unilateral or bilateral coxofemoral joint osteoarthritis.
  • To view the abstract of the clinical study presented at the VOS annual conference please visit the following:

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Retrieved on: 
Friday, February 23, 2024

If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Key Points: 
  • If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
  • “The CHMP’s positive opinion reinforces the impact QALSODY can have in SOD1-ALS and further demonstrates Biogen’s commitment to address the unmet needs of people living with ALS and neuromuscular diseases,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.
  • Trends towards improvement in the physical abilities of participants who received QALSODY were seen compared to those who received placebo, as measured by the ALS Functional Ratings Scale-Revised (ALSFRS-R).
  • Serious neurologic events, including myelitis and/or radiculitis; papilledema and elevated intracranial pressure; and aseptic meningitis have also been reported.

Children’s Hospital Los Angeles Study Finds Many Kids With Sickle Cell Anemia Lack Preventative Care

Retrieved on: 
Wednesday, March 6, 2024

Children with sickle cell anemia are vulnerable to serious infections and stroke, but many do not receive the preventative care that could help them stay healthier for longer, a Children’s Hospital Los Angeles study found.

Key Points: 
  • Children with sickle cell anemia are vulnerable to serious infections and stroke, but many do not receive the preventative care that could help them stay healthier for longer, a Children’s Hospital Los Angeles study found.
  • The researchers measured how many young children with sickle cell anemia received adequate preventative antibiotics to prevent infection and if children and adolescents with sickle cell anemia received annual brain ultrasounds to assess their stroke risk.
  • “What we found, unfortunately, was not what we’d hoped for,” says Ashaunta Anderson , MD, MPH, MSHS, Pediatrician at Children’s Hospital Los Angeles , who led the study.
  • Twice-daily doses of antibiotics, given consistently, can protect young children with sickle cell anemia from developing serious infections.

Rebamipide May Combat Low-Grade Inflammation in Post-COVID-19 Syndrome Patients

Retrieved on: 
Monday, February 19, 2024

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month.

Key Points: 
  • "This study revealed higher levels of lipopolysaccharide-binding protein, and lower levels of bacterial permeability protein in patients with post COVID syndrome.
  • Rebamipide, by reducing intestinal permeability, reduces endotoxin load, lowering the level of low-grade inflammation.
  • To explore Rebamipide's usefulness for rehabilitating SARS-CoV-2 post-COVID syndrome patients, researchers examined 62 patients, aged 42-55 years with post-COVID-19 syndrome using nonsteroidal anti-inflammatory drugs for joint pain.
  • Given the effects of SARS-CoV-2 on enterocytes, the results suggest that Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome.

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure

Retrieved on: 
Friday, February 16, 2024

Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

Key Points: 
  • Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.
  • "While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs."
  • Current treatment requires strict avoidance of the food(s) the patient is allergic to, and prompt administration of epinephrine to treat anaphylaxis should accidental exposures occur.
  • Xolair is the first FDA-approved medication to reduce allergic reactions to more than one type of food after accidental exposure.

Reverse Hip Replacement System Unveiled at Global Orthopedic Surgery Meeting

Retrieved on: 
Thursday, February 15, 2024

SAN FRANCISCO, Feb. 15, 2024 /PRNewswire/ -- Hip Innovation Technology, LLC (HIT), a medical device company developing innovative orthopedic device solutions to advance the quality of life and quality of care for patients, today announced that its flagship product, the Reverse Hip Replacement System (Reverse HRS) was showcased at the 2024 American Academy of Orthopaedic Surgeons (AAOS) annual meeting, taking place in San Francisco, CA from February 12 -16, 2024.

Key Points: 
  • "We are extremely excited that the Reverse HRS was featured at AAOS in the OrthoDome with a video of an actual hip replacement surgery narrated by Dr. Adolph Lombardi," said George Diamantoni, Hip Innovation Technology's Co-Founder and Chief Executive Officer.
  • The presentation featured high resolution video of Dr. Lombardi conducting a hip replacement with the new Reverse HRS.
  • The Bone & Joint Open journal, recently published the article, "Radiostereometric analysis and clinical outcomes of a novel reverse total hip system at two years."
  • Hip replacement surgery, or total hip arthroplasty, is one of the most common joint replacement procedures done in the United States.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA

Retrieved on: 
Tuesday, February 13, 2024

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • WVC is the largest veterinary conference that services the western part of the United States, and normally plays host to more than 15,000+ participants including many of the top industry professionals.
  • “We are incredibly excited to participate in this year’s Western Veterinary Conference.

Caregivers Cheer First Patients at New Intermountain Primary Children’s Hospital, Miller Family Campus in Lehi, Utah

Retrieved on: 
Monday, February 12, 2024

The Miller Family Campus’ Infusion Center opened for one day before the grand opening to give them the treatments they needed, closer to home.

Key Points: 
  • The Miller Family Campus’ Infusion Center opened for one day before the grand opening to give them the treatments they needed, closer to home.
  • Everyone at the new campus has been so amazing to work with!”
    The new Miller Family Campus is a full-service children’s hospital providing nearly all the same specialty pediatric services that patients receive at the Salt Lake Campus.
  • The Miller Family Campus is part of Intermountain Health’s Primary Promise to build the nation’s model health system for children.
  • For more information about the new Miller Family Campus in Lehi, visit primarychildrens.org/lehi .

Chiesi Global Rare Diseases Presents Long-Term Data on Treatment with Velmanase Alfa in Alpha-Mannosidosis and Announces Additional Presentations at the 20th Annual WORLDSymposium™ Research Meeting

Retrieved on: 
Thursday, February 8, 2024

BOSTON, Feb. 8, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the presentation of long-term data from up to 12 years of treatment with velmanase alfa in patients with alpha-mannosidosis (AM). The company also announced the presentation of immunogenicity and tolerability data from its pegunigalsidase alfa clinical trial program in Fabry disease, as well as analyses of the prevalence, diagnosis, and progression of these rare lysosomal storage disorders. The data are being presented during the 20th Annual WORLDSymposium™ Research Meeting that is being held February 4-9, 2024, in San Diego, California.

Key Points: 
  • The data are being presented during the 20th Annual WORLDSymposium™ Research Meeting that is being held February 4-9, 2024, in San Diego, California.
  • Several poster presentations are highlighting immunogenicity and tolerability data from the pegunigalsidase alfa clinical trial program in Fabry disease.
  • The analysis includes 108 patients, 27 (25%) of whom were ADA+ before receiving their first dose of pegunigalsidase alfa.
  • There was a low incidence of de novo ADAs (n=17) occurring predominantly in the first year of treatment with pegunigalsidase alfa.

San Jose Wellness Center, NexGen Health, Elevates Wellness Offerings with the Introduction of BPC 157 Peptide Therapy

Retrieved on: 
Wednesday, February 7, 2024

SAN JOSE, Calif., Feb. 7, 2024 /PRNewswire/ -- NexGen Health, a prominent wellness clinic located in San Jose, California, is pleased to announce the integration of BPC 157 Peptide Therapy into its comprehensive suite of specialized wellness services. This cutting-edge therapy is poised to invigorate the body's innate healing processes, offering renewed hope to individuals seeking optimal health and well-being.

Key Points: 
  • NexGen Health improves patient care by introducing BPC 157 peptide therapy in San Jose, California, empowering healing, and wellness.
  • SAN JOSE, Calif., Feb. 7, 2024 /PRNewswire/ -- NexGen Health, a prominent wellness clinic located in San Jose, California, is pleased to announce the integration of BPC 157 Peptide Therapy into its comprehensive suite of specialized wellness services.
  • "Our commitment to offering BPC 157 Peptide Therapy reflects our passion for providing our patients with the latest advancements in regenerative medicine," says Ilbra Petros, Director of NexGen Health.
  • Our commitment to offering BPC 157 Peptide Therapy reflects our passion for providing our patients with the latest advancements in regenerative medicine," says Ilbra Petros, Director of NexGen Health.